Bioequivalence of Two Commercial Amoxicillin Suspensions

Overview

The aim of the present study was to compare the pharmacokinetic profiles and to evaluate the bioequivalence of two commercial amoxicillin-suspension formulations in healthy Brazilian volunteers.

Full Title of Study: “Bioequivalence Study of Two Commercial Amoxicillin Suspension Formulations in Healthy Human Volunteers”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Crossover Assignment
    • Primary Purpose: Basic Science
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: May 2005

Detailed Description

Under fasting condition, 25 volunteers (13 males and 12 females) were included in this randomized, open-label, two-period crossover (1-week washout interval) bioequivalence study. Blood samples were collected at pre-dose (0h) and 0.5, 1, 1.33, 1.66, 2, 2.5, 3, 4, 6, 8 and 12 hours after drug ingestion. Pharmacokinetic parameters (Cmax, Tmax, T1/2, Area-under-curve0-12h and Area-under-curve0-inf) were calculated from plasma concentrations for both formulations in each subject.

Interventions

  • Drug: amoxicillin
    • Comparison of pharmacokinetics of both formulations

Arms, Groups and Cohorts

  • Active Comparator: Amoxi-Ped
    • Single dose of 500 mg amoxicillin – AMOXI-PED – was administered after a 12-hour overnight fast.
  • Active Comparator: Amoxil
    • Single dose of 500 mg amoxicillin – AMOXIL – was administered after a 12-hour overnight fast.

Clinical Trial Outcome Measures

Primary Measures

  • Changes in plasmatic amoxicillin concentrations along time measured by HPLC.
    • Time Frame: Change from baseline to 12 hours
    • Amoxicillin were extracted from plasma by precipitating plasma proteins with acetonitrile. Amoxicillin plasmatic concentration was accessed every 30 minutes until 3h hours after drug administration and every 2h after this time until 12h of drug administration. Drug plasmatic concentrations were obtained by using a HPLC method.

Participating in This Clinical Trial

Inclusion Criteria

  • negative to HIV, hepatitis B virus, hepatitis C virus, addictive drugs and pregnancy test for women – age between 19 and 46 years – weight between 52 and 85 kg and body mass index between 17.6 and 28.4kg/m2 – ability to provide written consent – laboratory exam results within the normal range for healthy individuals and/or medically acceptable defined by a clinical investigator; – feeding habits consistent with the standardization of the study Exclusion Criteria:

  • pregnancy – history of hypersensitivity to penicillins (normal or idiosyncratic drug reaction) – any evidence of dysfunction or clinically significant deviation from normal – history of any psychiatric illness that might compromise the ability to provide written consent – history of gastrointestinal disease, hepatic, renal, pulmonary, cardiovascular, hematological, neurological or diabetes or glaucoma – active smoker – consumption of more than 5 cups of coffee or tea per day – history of drug dependence or abuse of alcohol consumption – use of enzymatic-inducers drugs within 30 days or any systemic medication (including prescription drugs, such as painkillers, hepatoprotective, influenza, etc) within 14 days before the start of the study – participation in any clinical study in 9 weeks prior to the study – have lost or donated more than 350 mL of blood in the last three months – have been subjected to abnormal diet for any reason (therapeutic, aesthetic, religious, etc.) – did not have adequate venous access.

Gender Eligibility: All

Minimum Age: 19 Years

Maximum Age: 46 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • University of Campinas, Brazil
  • Collaborator
    • Stiefel, a GSK Company
  • Provider of Information About this Clinical Study
    • Principal Investigator: Francisco Groppo, Full Professor – University of Campinas, Brazil
  • Overall Official(s)
    • Francisco C Groppo, PhD, Principal Investigator, University of Campinas, Brazil
    • Ana PP Cione, Chem., Study Chair, BIOAGRI Laboratórios Ltda

References

Baglie S, Rosalen PL, Franco LM, Ruenis AP, Baglie RC, Franco GC, Silva P, Groppo FC. Comparative bioavailability of 875 mg amoxicillin tablets in healthy human volunteers. Int J Clin Pharmacol Ther. 2005 Jul;43(7):350-4. doi: 10.5414/cpp43350.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.